CTXR (Citius Pharmaceuticals Inc.) stock: $0.60, $16.5M market cap, $17.0M cash, -$0.5M EV, $36.0M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Pipeline assets
LYMPHIR
Approved · Active Modality: engineered IL-2 diphtheria toxin fusion protein
Aliases denileukin diftitox
Target IL-2 receptor
Indications- Cutaneous T-cell lymphoma (CTCL, persistent/recurrent) (Approved)
Status note FDA approved; in-licensed Sep 2021, now owned by Citius Oncology. Distributed in the US via specialty distributors and internationally via Named Patient Program; limited operating revenue commenced Dec 2025.
Mino-Lok
Stage not disclosed · Active Modality: antibiotic lock solution
Partnerships Novel Anti-Infective Therapeutics (NAT): exclusive worldwide sub-licensable license to develop and commercialize Mino-Lok; $90K annual maintenance fee until commercial sales.
Indications- Catheter-related bloodstream infections (CRBSI) (Stage not disclosed)
Status note Minocycline + edetate + ethanol lock to salvage infected central venous catheters. FDA meeting provided pathway to a future NDA submission (505(b)(2)); combination product. No phase or filing date stated in excerpts.
Halo-Lido
Stage not disclosed · Active Modality: topical formulation
Indications- Hemorrhoids (Stage not disclosed)
Status note Corticosteroid-lidocaine topical intended for anti-inflammatory and anesthetic relief in hemorrhoids; 505(b)(2) path contemplated; no trial or filing timing stated.
NoveCite
Stage not disclosed · Active Modality: mesenchymal stem cell therapy
Partnerships Eterna Therapeutics (successor to Novellus/Brooklyn): exclusive worldwide license for stem cell therapy in acute pneumonitis; $5M paid; Eterna holds 25% of NoveCite equity (Citius 75%, consolidated subsidiary).
Indications- ARDS / acute pneumonitis (Stage not disclosed)
Status note Mesenchymal stem cell therapy for ARDS/acute pneumonitis of any etiology; no trial stage stated in excerpts.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.